Home Stock

Stock Research: NewAmsterdam Pharma Company

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

NewAmsterdam Pharma Company

NMQ:NAMS NL00150012L7
44
  • Value
    18
  • Growth
    47
  • Safety
    Safety
    37
  • Combined
    25
  • Sentiment
    98
  • 360° View
    360° View
    44
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

more

ANALYSIS: With an Obermatt 360° View of 44 (better than 44% compared with alternatives), overall professional sentiment and financial characteristics for the stock NewAmsterdam Pharma Company are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for NewAmsterdam Pharma Company. The consolidated Sentiment Rank has a good rank of 98, which means that professional investors are more optimistic about the stock than for 98% of alternative investment opportunities. But all other ranks are below average. The consolidated Value Rank has a rank of 18, which means that the share price of NewAmsterdam Pharma Company is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 47, meaning that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. This means that growth is lower than for 47% of competitors in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 37 which means that the company has a riskier financing structure than 63% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Strongest Rank Price vs. Sales (P/S)
Weakest Rank Leverage
Country Netherlands
Industry Biotechnology
Size Small
Website ir.newamsterdampharma.com
Index
NASDAQ
NewAmsterdam Pharma Company stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 26-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
18 n/a n/a n/a
Growth
47 n/a n/a n/a
Safety
Safety
37 n/a n/a n/a
Sentiment
98 n/a n/a n/a
360° View
360° View
44 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
54 n/a n/a n/a
Opinions Change
83 n/a n/a n/a
Pro Holdings
n/a n/a n/a n/a
Market Pulse
94 n/a n/a n/a
Sentiment
98 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
18 n/a n/a n/a
Growth
47 n/a n/a n/a
Safety Safety
37 n/a n/a n/a
Combined
25 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
1 n/a n/a n/a
Price vs. Earnings (P/E)
94 n/a n/a n/a
Price vs. Book (P/B)
15 n/a n/a n/a
Dividend Yield
1 n/a n/a n/a
Value
18 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
60 n/a n/a n/a
Profit Growth
1 n/a n/a n/a
Capital Growth
54 n/a n/a n/a
Stock Returns
71 n/a n/a n/a
Growth
47 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
100 n/a n/a n/a
Refinancing
18 n/a n/a n/a
Liquidity
25 n/a n/a n/a
Safety Safety
37 n/a n/a n/a

Similar Stocks

Discover high‑ranked alternatives to NewAmsterdam Pharma Company and broaden your portfolio horizons.

Randstad

AEX:RAND
Country: Netherlands
Industry: HR- & Employment Services
Size: X-Large
Full Stock Analysis

Richter Gedeon

BUD:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Faes Farma

MCE:FAE
Country: Spain
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

STMicroelectronics

PAR:STMPA
Country: Netherlands
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

Only the professional market sentiment is positive. The stock is expensive, has low growth, and low financial safety. This is a weak investment proposition. Only a small, highly-speculative investment may be justified by investors who strongly believe the positive sentiment points to an positive future.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews